[go: up one dir, main page]

GT201200275A - Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores - Google Patents

Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Info

Publication number
GT201200275A
GT201200275A GT201200275A GT201200275A GT201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A
Authority
GT
Guatemala
Prior art keywords
robo1
fusion protein
tumor treatment
protein
slit
Prior art date
Application number
GT201200275A
Other languages
English (en)
Inventor
Blanche Francis
Cameron Béatrice
Dabdoubi Tarik
Dol-Gleizes Frédérique
Fons Pierre
Herault Jean-Pascal
Prades Catherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200275A publication Critical patent/GT201200275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA PROTEÍNA RECOMBINANTE ROBO1FC Y SU UTILIZACIÓN PARA TRATAR LAS ENFERMEDADES EN LAS QUE SE SOBREEXPRESA UNA PROTEÍNA SLIT, PARTICULARMENTE CÁNCER. SE REFIERE IGUALMENTE A UNA COMPOSICION QUE COMPRENDE TAL PROTEÍNA RECOMBINANTE. OTRO ASPECTO DE LA INVENCIÓN CONSISTE EN LA UTILIZACIÓN DE UNA MOLÉCULA ROBO1-FC COMO HERRAMIENTA DE DIAGNÓSTICO PARA DETECTAR LA SOBREEXPRESIÓN DE UNA MOLÉCULA DE LA FAMILIA SLIT EN UN PACIENTE.
GT201200275A 2010-04-14 2012-10-11 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores GT201200275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
GT201200275A true GT201200275A (es) 2014-01-24

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200275A GT201200275A (es) 2010-04-14 2012-10-11 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Country Status (27)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
PH (1) PH12012502044A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69415627T2 (de) 1993-04-05 1999-06-17 Daikin Industries, Ltd., Osaka Polytetrafluorethylenfaser, baumwollartiges, diese faser enthaltendes material, und verfahren zu deren herstellung
US20130273049A1 (en) * 2010-12-23 2013-10-17 Sanofi Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
SG11201403746SA (en) 2012-01-05 2014-07-30 Boston Medical Ct Corp Slit-robo signaling for diagnosis and treatment of kidney disease
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
BR112019024742A2 (pt) * 2017-06-02 2020-06-16 Pfizer Inc. Proteínas robo2 recombinantes, composições, métodos e usos das mesmas
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
KR102353524B1 (ko) * 2019-02-27 2022-01-20 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 골 관련 질환 예방 또는 치료용 조성물
CA3136663A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production
TW202511284A (zh) * 2023-09-14 2025-03-16 大陸商北京拓界生物醫藥科技有限公司 包含robo結構域的蛋白及其醫藥用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP2003517262A (ja) * 1997-10-20 2003-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経誘導に含まれるポリペプチド及び核酸のファミリーであるｒｏｂｏ
NZ507063A (en) 1998-04-02 2003-11-28 Rigel Pharmaceuticals Inc Self-dimerising peptides causing the formation of compact structures
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
US20080153104A1 (en) * 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
WO2005073383A2 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
US20130195881A1 (en) * 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
MX2010001975A (es) 2007-08-29 2010-03-10 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
IL222382A (en) 2016-06-30
CN102884076A (zh) 2013-01-16
CA2796303A1 (fr) 2011-10-20
CR20120508A (es) 2012-11-01
UY33334A (es) 2011-12-01
FR2958936A1 (fr) 2011-10-21
PE20130199A1 (es) 2013-03-09
IL222382A0 (en) 2012-12-31
MX338981B (es) 2016-05-06
US9493529B2 (en) 2016-11-15
US20130039912A1 (en) 2013-02-14
EP2558489A1 (fr) 2013-02-20
TN2012000473A1 (fr) 2014-01-30
PH12012502044A1 (en) 2017-07-26
SG184529A1 (en) 2012-11-29
AU2011239839A1 (en) 2012-11-08
KR20130059329A (ko) 2013-06-05
WO2011128561A1 (fr) 2011-10-20
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
EA201291044A1 (ru) 2013-04-30
TW201142024A (en) 2011-12-01
ECSP12012230A (es) 2012-11-30
CL2012002879A1 (es) 2013-03-22
AU2011239839B2 (en) 2015-08-20
MX2012011822A (es) 2012-11-12
MA34221B1 (fr) 2013-05-02
DOP2012000265A (es) 2013-02-28
NI201200155A (es) 2013-02-05
BR112012026020A2 (pt) 2016-06-28
AR080891A1 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
MX2015010372A (es) Objetivo terapeutico y de diagnostico para el cancer que comprende reactivos que se unen con dll3.
MX2014012381A (es) Terapia de combinacion para tratar cancer.
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
EP3164412A4 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
AR079052A1 (es) Tratamiento del accidente cerebrovascular isquemico agudo o sangrado intracraneal con activador tisular de plasminogeno (tpa) y eritropoyetina carbamilada
UY35921A (es) Necrostatina-1 y derivados como retardadores de la degeneración axonal
UA58006U (ru) Средство для лечения дерматологических заболеваний и комплексного оздоровления тканей и органов c усилением защитных свойств организма